Changeflow GovPing Pharma & Drug Safety STAT3 inhibitor prodrug patent compositions
Routine Notice Added Final

STAT3 inhibitor prodrug patent compositions

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.

What changed

USPTO issued patent grant US12594265B2 to Ohio State Innovation Foundation for methods and compositions related to STAT inhibitor prodrugs, specifically targeting STAT3. The patent protects pharmaceutical compositions comprising prodrug inhibitors of STAT and their use in treating inflammatory disorders and cancers. Filing date was August 22, 2022 (Application No. 17821286), with 19 claims granted.

This patent grant creates intellectual property rights but imposes no regulatory compliance obligations on pharmaceutical companies or other entities. Organizations developing STAT3 inhibitors or related cancer/inflammatory disease therapeutics should consider potential patent infringement implications and may need to obtain licenses from the assignee for commercialization activities. No compliance deadlines or penalties are associated with this notice.

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods and compositions for inhibition of STAT3

Grant US12594265B2 Kind: B2 Apr 07, 2026

Assignee

Ohio State Innovation Foundation

Inventors

Yuhong Yang, Chenglong Li, Michael Racke

Abstract

In one aspect, the disclosure relates to prodrug compositions of a STAT inhibitor compound. In some aspects, the STAT is STAT3. Disclosed are pharmaceutical compositions comprising the prodrug inhibitors of STAT. In various aspects, the prodrug inhibitors of STAT can be used in methods of treating an inflammatory disorder, including multiple sclerosis, or a disorder of uncontrolled cellular proliferation, such as a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

CPC Classifications

A61K 31/18 C07D 275/06

Filing Date

2022-08-22

Application No.

17821286

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594265B2
Docket
17821286

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!